Drug Trial Radar · NCT04068896
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Last checked: Nov 19, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Oct 16, 2019
Primary completion
Sep 21, 2023
Study completion Jan 8, 2024
Sponsor
- Lead sponsor
- NGM Biopharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
Conditions
- Pancreatic Cancer
- Metastatic Castration-resistant Prostate Cancer
- Bladder Cancer
- Melanoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Gastric Cancer
- Esophageal Cancer
- Ovarian Cancer
- Head Neck Squamous Cell Carcinoma
- Prostate Cancer
Interventions
NGM120 30mgBiological
NGM120 30mg Subcutaneous Injection
NGM120 100mgBiological
NGM120 100mg Subcutaneous Injection
NGM120 30mg with Gemcitabine and AbraxaneBiological
NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
NGM120 100mg with Gemcitabine and AbraxaneBiological
NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
NGM120 100mg Q3WBiological
NGM120 100mg Subcutaneous Injection every 3 weeks
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Determine the Safety and Tolerability of NGM120 in SubjectsTime frame: From enrollment to end of treatment up to 24 months
- To Determine the Safety and Tolerability of NGM120Time frame: From enrollment to end of treatment up to 24 months
- To Determine the Safety and Tolerability of NGM120Time frame: From enrollment to end of treatment up to 24 months
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
NGM Clinical Study Site
Tucson, Arizona
NGM Clinical Study Site
Los Angeles, California
NGM Clinical Study Site
Los Angeles, California
NGM Clinical Study Site
Sacramento, California
NGM Clinical Study Site
San Diego, California
NGM Clinical Study Site
Santa Monica, California
NGM Clinical Study Site
Aurora, Colorado
NGM Clinical Study Site
Washington D.C., District of Columbia
NGM Clinical Study Site
Miami, Florida
NGM Clinical Study Site
Chicago, Illinois
NGM Clinical Study Site
Baltimore, Maryland
NGM Clinical Study Site
Cincinnati, Ohio
NGM Clinical Study Site
Philadelphia, Pennsylvania
NGM Clinical Study Site
Charleston, South Carolina
NGM Clinical Study Site
Myrtle Beach, South Carolina
NGM Clinical Study Site
Nashville, Tennessee
NGM Clinical Study Site
Dallas, Texas
NGM Clinical Study Site
Houston, Texas
NGM Clinical Study Site
Seattle, Washington
NGM Clinical Study Site
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.